1.
Clin Rheumatol
; 29(5): 551-3, 2010 May.
Article
En
| MEDLINE
| ID: mdl-20119843
An increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved and serologic abnormalities improved after infliximab was ceased. A flare of AS symptoms after 2 months prompted cautious introduction of an alternative TNFi, etanercept. At 14 months follow-up, neither clinical nor serologic flare of lupus had occurred. To our knowledge, this is the third reported case of infliximab-related lupus that did not recur on switching to an alternative TNFi.
Antibodies, Monoclonal/pharmacology , Immunoglobulin G/pharmacology , Lupus Erythematosus, Systemic/drug therapy , Spondylitis, Ankylosing/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Antirheumatic Agents/pharmacology , Autoimmunity , DNA/metabolism , Etanercept , Female , Humans , Inflammation , Infliximab , Lupus Erythematosus, Systemic/blood , Quality of Life , Receptors, Tumor Necrosis Factor , Spondylitis, Ankylosing/blood , Time Factors